Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. (LFWD) reported third-quarter 2026 revenue of $5.428 million, down 12% from $6.195 million a year earlier. AlterG revenue rose 18% to $3.6 million; ReWalk Personal exoskeleton revenue was $1.7 million, compared with $3.0 million, reflecting lower U.S. sales during the channel-partner transition and lower European revenue.
Gross margin fell to 27.4% from 43.7%. Lifeward attributed the decrease primarily to foreign-exchange fluctuations, higher freight costs and tariffs, and revenue-sharing expense tied to the Oratech acquisition. Operating expenses were $7.457 million versus $5.847 million; operating loss was $5.970 million versus $3.140 million. Net loss was $5.052 million, or $1.32 per share, compared with $3.170 million, or $2.37 per share.
Management called the quarter transitional and said the channel-partner model can create near-term timing gaps; it believes established providers could broaden ReWalk access and support long-term revenue growth. Unrestricted cash was $4.548 million as of September 30, 2026, compared with $2.169 million as of December 31, 2025.
Lifeward Ltd. (LFWD) reported third-quarter revenue of $5.428 million, down from $6.195 million a year earlier, and a net loss of $5.052 million versus $3.170 million. ReWalk revenue fell $1.3 million, mainly from lower U.S. and European sales and near-term effects of its transition to channel partners; higher AlterG revenue partly offset the decline. Nine-month revenue was $15.974 million versus $16.953 million, and net loss was $27.364 million versus $14.566 million. Acquired Oratech in-process research and development generated $4.947 million in nine-month R&D expense.
During the first nine months, operating activities used $16.064 million in cash and financing activities provided $18.502 million; cash and cash equivalents were $4.548 million as of September 30, 2026. Management concluded existing cash resources were insufficient to fund planned operations for at least 12 months from issuance and that substantial doubt exists about Lifeward’s ability to continue as a going concern. Lifeward plans to raise additional capital.
In November 2026, a Belgian authority said it believes Neo and Neo+ Anti-Gravity Treadmills should be classified at least as Class IIa devices. Lifeward is evaluating and implementing corrective actions; it does not currently expect EU marketing to be interrupted during the applicable transition period, while marketing afterward depends on timely completion of the regulatory process.
Lifeward Ltd. (LFWD) director Ariel Kallner reported no securities beneficially owned.
Lifeward Ltd. reported results from its October 30, 2026 shareholder meeting: 2,036,125 ordinary shares, approximately 71.7% of the 2,838,715 ordinary shares issued and outstanding as of September 30, 2026, were present or voted, constituting a quorum. Shareholders approved every proposal except the three-year renewal of the officers’ and directors’ Compensation Policy, which failed to receive the required majority of ordinary shares voted, excluding abstentions, by non-controlling shareholders without a personal interest.
Shareholders approved issuance of ordinary shares upon conversion of the Notes and exercise of the Warrants, including issuances in excess of the Exchange Cap. Haggai Zamir and Avi Gabay were re-elected as Class III directors through the 2029 annual meeting; Ariel Kallner was elected an external director for a three-year term beginning November 11, 2026. Shareholders approved compensation for Josh Hexter, Interim Chief Executive Officer, and re-appointed Kost Forer Gabbay & Kasierer as independent registered public accounting firm for 2026. Ronen Tsimerman’s Chief Financial Officer appointment is effective November 1, 2026, unaffected by the policy vote; his employment agreement will be effective as of November 1, 2026 once a compensation policy is in effect.
Lifeward Ltd. (LFWD) Chief Financial Officer Ronen Tsimerman reported no securities as beneficially owned. No transactions are listed.
Lifeward Ltd. appointed Ronen Tsimerman as chief financial officer, principal financial officer and principal accounting officer, effective November 1, 2026. The Board made the appointment on October 26. Tsimerman most recently served as CFO of Scopio Labs Ltd. from August through October 2026 and previously was CFO of IceCure Medical Ltd. from May 2017 to August 2026.
Lifeward and Tsimerman will enter into an employment agreement subject to shareholder approval of the renewed compensation policy at the annual general meeting scheduled for October 30, 2026. Proposed terms include a gross monthly base salary of NIS 70,000, an annual performance-based bonus set each year by the compensation committee and Board with a target of not less than four monthly salaries, and a transaction bonus. Bonuses are subject to the policy and required approvals. The proposed agreement provides for three months’ termination notice, increasing to four months for either party following a change in the CEO, including appointment of a permanent CEO.
Lifeward Ltd. said Rami Aviram, appointed Chief Financial Officer, principal financial officer and principal accounting officer effective November 1, 2026, informed the company on October 4, 2026 that he had decided not to join and would not assume those roles.
Josh Hexter, identified as interim Chief Executive Officer, will continue as interim principal financial officer and principal accounting officer until a successor is appointed. He will receive no additional compensation for continuing in these capacities. Lifeward is conducting a search for a permanent Chief Financial Officer and will announce a successor when the search concludes.
Lifeward Ltd. designated Josh Hexter, its Interim Chief Executive Officer and principal executive officer, to also serve as interim principal financial officer and principal accounting officer effective October 1, 2026. He will serve in those capacities until November 1, 2026, when Rami Aviram’s previously disclosed appointment as Chief Financial Officer, principal financial officer and principal accounting officer becomes effective. Hexter will receive no additional compensation for the designation.
Almog Adar’s departure as Chief Financial Officer, principal financial officer and principal accounting officer became effective September 30, 2026.
Lifeward Ltd. (LFWD) seeks votes at its October 30, 2026 annual and extraordinary meeting on nine proposals covering director elections, external-director and director compensation, Interim CEO Josh Hexter’s compensation, issuance of ordinary shares above the exchange cap upon conversion or exercise of certain securities, a three-year compensation-policy renewal, auditor reappointment, executive pay and future say-on-pay frequency. The Board recommends “FOR” Proposals 1–8 and “EVERY YEAR” for Proposal 9; shareholders of record on September 30, 2026 may vote.
Proposals 2, 3, 4 and 6 also require a “Special Majority” under Israeli law: in addition to an ordinary majority, either a majority of eligible votes cast must support the proposal or opposing votes by non-controlling shareholders without a personal interest must not exceed 2% of outstanding voting power. For 2025, Lifeward says revenue and net-income targets were not achieved, so no bonus was paid for those corporate goals; individual-goal bonuses were $22,050 for CFO Almog Adar and $6,329 for former VP Jeannine Lynch. Former CEO Mark Grant received a guaranteed $177,625 bonus.